More recently, CAR has been reported to regulate both lipid and glucose metabolism and has been a potential therapeutic target for several metabolic diseases, such as obesity [15,59], atherosclerosis [60,61], NAFLD [62,63], and T2DM [64,65], due to its ability to balance the endogenous homeostasis of components, including glucose, steroids, bile acids, bilirubin, and thyroid hormone. The gene discussed is NR1I3; the disease is metabolic disease.